Partnering Opportunities

ASINEX is interested in research, development and commercialization relationships with pharmaceutical and biotechnology companies.

ASINEX has mastered its Compound-to-Target™ platform that facilitates translation of innovative small molecule and macrocyclic chemistry into pre-clinical leads focusing on specific oncogenic pathways:

  •  Apoptotic pathways
  •  Cyclin-dependent kinase pathways
  •  Wnt/β-catenin signaling pathway 

In addition to oncology, the platform provides valuable starting points for antibacterial R&D.

For more information, please contact us